Table 5 Clinical trials of nab-paclitaxel in sarcomas currently recruiting
From: Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
Title | Phase | Status | Histological subtypes | Number of patients | Collaborators | Dates | NCT Number |
|---|---|---|---|---|---|---|---|
Nab-paclitaxel and gemcitabine in advanced STS. | 1 and 2 | Recruiting | STS | 45 | Swiss Group for Clinical Cancer Research | Start: October 2018 Completion: October 2022 | NCT03524898 |
Nab-paclitaxel and gemcitabine for recurrent/refractory sarcoma. | 2 | Recruiting | Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, STS | 72 | H. Lee Moffitt Cancer Center and Research Institute National Pediatric Cancer Foundation | Start: October 2016 Completion: March 2021 | NCT02945800 |
Trial of nab-paclitaxel in patients with desmoid tumors and multiply relapsed/refractory desmoplastic small round cell tumors and Ewing sarcoma. | 2 | Recruiting | Desmoid tumors, Desmoplastic small round cell tumors, Ewing sarcoma | 61 | Grupo Espanol de Investigacion en Sarcomas | Start: May 2017 Completion: September 2020 | NCT03275818 |
Nab-paclitaxel in combination with gemcitabine for pediatric relapsed and refractory solid tumors. | 1 | Recruiting | Dediatric relapsed and refractory solid tumors | 24 | Emory University, Celgene Corporation | Start: August 2018 Completion: May 2022 | NCT03507491 |